UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Follicular Lymphoma
- Acute Leukemia
- Acute Lymphoblastic Leukemia/Lymphoma
- Acute Myeloid Leukemia
- Biphenotypic/Undifferentiated/Prolymphocytic Leukemias
- Mantle Cell Lymphoma
- Relapsed T-Cell Lymphoma
- Myeloproliferative Neoplasms/Myelofibrosis
- Marginal Zone B Cell Lymphoma
- Multiple Myeloma
- Lymphoplasmacytic Lymphoma
- Myelodysplastic Syndrome
- Relapsed Small Lymphocytic Lymphoma
- Relapsed Multiple Myeloma
- Bone Marrow Failure Syndromes
- Prolymphocytic Leukemia
- Burkitt's Lymphoma
- Relapsed Chronic Lymphocytic Leukemia
- Plasma Cell Leukemia
- Chronic Myelogenous Leukemia
- Hodgkin Lymphoma
- MRD Positive Leukemia
- Natural Killer Cell Malignancies
- Large Cell Lymphoma
- Leukemia or MDS in Aplasia
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Younger than 75 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02722668
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Claudio Brunstein, MD, PhD University of Minnesota
Get Well Soon